Encyclopedia of Systems Biology

2013 Edition
| Editors: Werner Dubitzky, Olaf Wolkenhauer, Kwang-Hyun Cho, Hiroki Yokota

Pathway Targeting, Antimycobacterial Drug Design

  • Deepak SharmaEmail author
  • Avadhesha Surolia
Reference work entry
DOI: https://doi.org/10.1007/978-1-4419-9863-7_568



Delineation of (mycobacterial) pathways/networks is essential for the identification of novel target(s) so as to hit the pathogen at its vulnerable weakest. In any given pathway or network, the potential (antitubercular) drug targets are the nonhomologous proteins that form (1) unique nodes including chokepoints (enzymes that uniquely consume/produce a metabolite) and (2) nodes with a high  degree centrality. For instance, the metabolic pathways/networks have been extensively implicated in antitubercular drug discovery over recent years (Ducati et al. 2007; Raman et al. 2009; Kim et al. 2010).


Tuberculosis (TB) has scourged the humankind for centuries, earning morbid nicknames such as The White Plague and The Captain of all the Men of Death. Robert Koch identified the causative agent, Mycobacterium tuberculosis, in 1882 and the first – and so far the only – vaccine against the disease, BCG (bacillus...

This is a preview of subscription content, log in to check access.


  1. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D et al (1998) Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393:537–544PubMedGoogle Scholar
  2. Ducati RG, Basso LA, Santos DS (2007) Mycobacterial shikimate pathway enzymes as targets for drug design. Curr Drug Targets 8:423–435PubMedGoogle Scholar
  3. Kim TY, Kim HU, Lee SY (2010) Metabolite-centric approaches for the discovery of antibacterials using genome-scale metabolic networks. Metab Eng 12:105–111PubMedGoogle Scholar
  4. Kumar A, Toledo JC, Patel RP, Lancaster JR Jr, Steyn AJ (2007) Mycobacterium tuberculosis DosS is a redox sensor and DosT is a hypoxia sensor. Proc Natl Acad Sci USA 104:11568–11573PubMedGoogle Scholar
  5. Majumdar SD, Sharma D, Vashist A, Kaur K, Taneja NK, Chauhan S et al (2010) Co-expression of DevR and DevR(N)-Aph proteins is associated with hypoxic adaptation defect and virulence attenuation of Mycobacterium tuberculosis. PLoS One 5:e9448PubMedGoogle Scholar
  6. Murphy DJ, Brown JR (2008) Novel drug target strategies against Mycobacterium tuberculosis. Curr Opin Microbiol 11:422–427PubMedGoogle Scholar
  7. Parida BK, Douglas T, Nino C, Dhandayuthapani S (2005) Interactions of anti-sigma factor antagonists of Mycobacterium tuberculosis in the yeast two-hybrid system. Tuberculosis (Edinb) 85:347–355Google Scholar
  8. Raman K, Vashisht R, Chandra N (2009) Strategies for efficient disruption of metabolism in Mycobacterium tuberculosis from network analysis. Mol Biosyst 5:1740–1751PubMedGoogle Scholar
  9. Rodrigue S, Provvedi R, Jacques PE, Gaudreau L, Manganelli R (2006) The σ factors of Mycobacterium tuberculosis. FEMS Microbiol Rev 30:926–941PubMedGoogle Scholar
  10. Sachdeva P, Misra R, Tyagi AK, Singh Y (2010) The sigma factors of Mycobacterium tuberculosis: regulation of the regulators. FEBS J 277:605–626PubMedGoogle Scholar
  11. Schreiber M, Res I, Matter A (2009) Protein kinases as antibacterial targets. Curr Opin Cell Biol 21:325–330PubMedGoogle Scholar
  12. Spigelman MK (2007) New tuberculosis therapeutics: a growing pipeline. J Infect Dis 196(Suppl 1):S28–S34PubMedGoogle Scholar
  13. Timm J, Post FA, Bekker LG, Walther GB, Wainwright HC, Manganelli R et al (2003) Differential expression of iron-, carbon-, and oxygen-responsive mycobacterial genes in the lungs of chronically infected mice and tuberculosis patients. Proc Natl Acad Sci USA 100:14321–14326PubMedGoogle Scholar
  14. Tyagi JS, Sharma D (2004) Signal transduction systems of mycobacteria with special reference to M. tuberculosis. Curr Sci 86:93–102Google Scholar
  15. Voskuil MI, Schnappinger D, Visconti KC, Harrell MI, Dolganov GM, Sherman DR, Schoolnik GK (2003) Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J Exp Med 198:705–713PubMedGoogle Scholar
  16. Wayne LG, Sohaskey CD (2001) Nonreplicating persistence of Mycobacterium tuberculosis. Annu Rev Microbiol 55:139–163PubMedGoogle Scholar
  17. Williams KJ, Duncan K (2007) Current strategies for identifying and validating targets for new treatment-shortening drugs for TB. Curr Mol Med 7:297–307PubMedGoogle Scholar
  18. Zhang Y (2005) The magic bullets and tuberculosis drug targets. Annu Rev Pharmacol Toxicol 45:529–564PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2013

Authors and Affiliations

  1. 1.Translational Health Science and Technology InstituteGurgaonIndia
  2. 2.Molecular Biophysics Unit, Indian Institute of ScienceBangaloreIndia